Katelyn McGlaughlin
Gerontology · Fort Myers, FLNPI 1366295552
Payments from drug & device makers
Across 211 payments — averaging $22.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$529
- Merck$447
- Pfizer$359
- Johnson & Johnson$350
- Daiichi Sankyo Inc.$347
- Incyte Corporation$269
- plus $2K from 35 others
What the payments were for
- Food & beverage$4,59796%
- Education$1744%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 23 | $529 |
| Merck | 19 | $447 |
| Pfizer | 16 | $359 |
| Johnson & Johnson | 16 | $350 |
| Daiichi Sankyo Inc. | 13 | $347 |
| Incyte Corporation | 9 | $269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $199 |
| E.r. Squibb & Sons, L.L.C. | 9 | $180 |
| Sumitomo Pharma America, Inc. | 9 | $170 |
| Beone Medicines USA, Inc. | 7 | $149 |
| Bayer | 8 | $141 |
| Novartis | 6 | $128 |
| Bristol Myers Squibb | 5 | $126 |
| AbbVie | 5 | $112 |
| Dendreon Pharmaceuticals LLC | 4 | $104 |
| Sanofi | 3 | $82 |
| Jazz Pharmaceuticals Inc. | 4 | $79 |
| GSK | 3 | $78 |
| Sobi, Inc | 4 | $78 |
| Gilead | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $70 |
| Puma Biotechnology, Inc. | 4 | $66 |
| Pharmacosmos Therapeutics Inc. | 3 | $58 |
| Stemline Therapeutics Inc. | 2 | $57 |
| Agios Pharmaceuticals, Inc. | 3 | $53 |
| Boehringer Ingelheim | 2 | $50 |
| Iovance Biotherapeutics, Inc. | 2 | $43 |
| Genmab U.S., Inc. | 2 | $42 |
| Exelixis Inc. | 2 | $38 |
| Array Biopharma Inc | 2 | $35 |
| Eisai Inc. | 2 | $33 |
| Blueprint Medicines Corporation | 1 | $27 |
| Geron Corporation | 1 | $27 |
| ADC Therapeutics America, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Legend Biotech USA Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
How this compares
$4,771 in reported general payments places this provider in the 90th percentile of 714 gerontology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $11,133 |
| Letrozole | 17 | $269 |
| Prochlorperazine Maleate | 16 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $359 | $11,13311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 714 gerontology providers in Florida.
Other gerontology in Fort Myers
- Deetta DebaultFort Myers$14K
- Heidi PapeshFort Myers$9K
- Johnny IqbalFort Myers$8K
- Francesca BarberaFort Myers$5K
- Noureen DhananiThe Villages$276K
- Flavius NascimentoCoral Springs$226K
- Michelle HartogWinter Park$90K
- Alejandra Rosales-CohenOrange City$88K
- Jennifer PacilettiAtlantis$66K
- Tatiana ClarkBradenton$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.